[go: up one dir, main page]

SG11202106700WA - Polypeptides comprising modified il-2 polypeptides and uses thereof - Google Patents

Polypeptides comprising modified il-2 polypeptides and uses thereof

Info

Publication number
SG11202106700WA
SG11202106700WA SG11202106700WA SG11202106700WA SG11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA
Authority
SG
Singapore
Prior art keywords
polypeptides
modified
Prior art date
Application number
SG11202106700WA
Inventor
John C Timmer
Brendan P Eckelman
Katelyn Mckabe Willis
Florian J Sulzmaier
Bryan R Becklund
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of SG11202106700WA publication Critical patent/SG11202106700WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202106700WA 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof SG11202106700WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789075P 2019-01-07 2019-01-07
PCT/US2020/012296 WO2020146221A1 (en) 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
SG11202106700WA true SG11202106700WA (en) 2021-07-29

Family

ID=69374426

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106700WA SG11202106700WA (en) 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof

Country Status (15)

Country Link
US (1) US20220089667A1 (en)
EP (1) EP3908596A1 (en)
JP (2) JP7594161B2 (en)
KR (1) KR20210113265A (en)
CN (1) CN113924311A (en)
AR (1) AR117770A1 (en)
AU (1) AU2020206672B2 (en)
BR (1) BR112021012294A2 (en)
CA (1) CA3125529A1 (en)
CL (1) CL2021001779A1 (en)
IL (1) IL284633A (en)
MX (1) MX2021008147A (en)
SG (1) SG11202106700WA (en)
TW (1) TWI874345B (en)
WO (1) WO2020146221A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000939PA (en) 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. NATURAL KILLER CELL PRODUCTION PROCESS AND COMPOSITION FOR CANCER TREATMENT
AU2019376076B9 (en) 2018-11-08 2025-06-19 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
WO2021041206A1 (en) 2019-08-23 2021-03-04 Synthorx, Inc. Il-15 conjugates and uses thereof
TW202124385A (en) 2019-09-10 2021-07-01 美商欣爍克斯公司 Il-2 conjugates and methods of use to treat autoimmune diseases
JP2023531876A (en) * 2020-06-30 2023-07-26 ジーアイ イノベーション， インコーポレイテッド Fusion protein comprising anti-LAG-3 antibody and IL-2 and use thereof
MX2022016532A (en) * 2020-07-02 2023-04-12 Inhibrx Inc Polypeptides comprising modified il-2 polypeptides and uses thereof.
IL302276A (en) 2020-10-23 2023-06-01 Asher Biotherapeutics Inc Fusion with CD8 antigen binding molecules to modulate immune cell function
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers
EP4259213A4 (en) * 2020-12-09 2024-11-20 Asher Biotherapeutics, Inc. Targeted cytokine construct for engineered cell therapy
CN112979782B (en) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 Polypeptide and application thereof
AU2022252307A1 (en) * 2021-03-31 2023-10-12 Anwita Biosciences, Inc. Fusion proteins, pharmaceutical compositions, and therapeutic applications
WO2023004305A1 (en) * 2021-07-20 2023-01-26 Inhibrx, Inc. Cd8-targeted modified il-2 polypeptides and uses thereof
CA3225092A1 (en) * 2021-07-20 2023-01-26 John C. Timmer Cd8-binding polypeptides and uses thereof
WO2023034740A1 (en) * 2021-08-30 2023-03-09 Inhibrx, Inc. Nkp46-binding polypeptides and uses thereof
TW202328171A (en) * 2021-08-30 2023-07-16 美商英伊布里克斯公司 Nkp46-targeted modified il-2 polypeptides and uses thereof
CN118019849A (en) * 2021-09-26 2024-05-10 上海药明生物技术有限公司 IL-2 variants and fusion proteins
TW202334193A (en) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof
JP2025528019A (en) * 2022-07-28 2025-08-26 プロヴィヴァ セラピューティクス （ホン コン） リミテッド IL-2 Procytokine Antibody Fusion Protein

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
BR9813365A (en) 1997-12-05 2004-06-15 Scripps Research Inst Method for Production and Humanization of a Mouse Monoclonal Antibody
DK1454138T3 (en) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokines with modulated selectivity
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005040395A1 (en) 2003-10-22 2005-05-06 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
KR20070003934A (en) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 In vitro test system to predict patient tolerability of therapeutics
CN1930300A (en) * 2004-03-05 2007-03-14 希龙公司 In vitro test system for predicting patient tolerability of therapeutic agents
MXPA06011199A (en) 2004-03-31 2007-04-16 Genentech Inc Humanized anti-tgf-beta antibodies.
CN102101885B (en) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 Human interleukin-II mutant of low-inductivity suppressor T cells and use thereof
ES2694564T3 (en) * 2011-02-10 2018-12-21 Roche Glycart Ag Interleukin-2 mutant polypeptides
KR102677704B1 (en) * 2012-05-30 2024-06-21 추가이 세이야쿠 가부시키가이샤 Target-tissue-specific antigen-binding molecule
EA201992609A1 (en) * 2014-02-06 2020-03-04 Ф.Хоффманн-Ля Рош Аг FILLED PROTEINS CONTAINING INTERLEUKIN-2 AND THEIR APPLICATIONS
AU2017206618A1 (en) * 2016-01-11 2018-07-05 Universität Zürich Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
CN115073581A (en) * 2016-05-04 2022-09-20 美国安进公司 Interleukin-2 muteins for expansion of T regulatory cells
KR102619015B1 (en) * 2017-03-15 2023-12-28 큐 바이오파마, 인크. How to Regulate Your Immune Response
WO2018184965A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
FI3606955T3 (en) * 2017-04-05 2025-01-08 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
CN111010866A (en) * 2017-05-24 2020-04-14 潘迪恩治疗公司 Targeted immune tolerance
US11542312B2 (en) * 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies

Also Published As

Publication number Publication date
AR117770A1 (en) 2021-08-25
BR112021012294A2 (en) 2021-09-08
KR20210113265A (en) 2021-09-15
US20220089667A1 (en) 2022-03-24
TW202043259A (en) 2020-12-01
MX2021008147A (en) 2021-08-11
WO2020146221A1 (en) 2020-07-16
JP2025013911A (en) 2025-01-28
JP2022516557A (en) 2022-02-28
JP7594161B2 (en) 2024-12-04
AU2020206672B2 (en) 2025-10-02
TWI874345B (en) 2025-03-01
CA3125529A1 (en) 2020-07-16
AU2020206672A1 (en) 2021-07-15
IL284633A (en) 2021-08-31
EP3908596A1 (en) 2021-11-17
CL2021001779A1 (en) 2022-03-04
CN113924311A (en) 2022-01-11

Similar Documents

Publication Publication Date Title
IL284633A (en) Polypeptides comprising modified il-2 polypeptides and uses thereof
IL281192A (en) Interleukin-2 polypeptide conjugates and their uses
IL287781A (en) Clec12a-binding polypeptides and uses thereof
IL274844A (en) Il-2 muteins and uses thereof
IL294052B1 (en) Fluoroalkyl-oxadiazoles and uses thereof
IL280808A (en) Ox40-binding polypeptides and uses thereof
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
IL287782A (en) Cd33-binding polypeptides and uses thereof
EP3813861A4 (en) Heparin-associated polypeptides and uses thereof
GB2600592B (en) Polypeptide and use thereof
SG11202006669RA (en) Peptides and uses thereof
IL287503A (en) Thiosemicarbazates and uses thereof
GB201819200D0 (en) Polypeptide and uses thereof
IL309885A (en) Alpha-sheet polypeptides and their use
GB202109082D0 (en) Polypeptides and uses thereof
EP4081235A4 (en) Heparin-associated polypeptides and uses thereof
EP3947418C0 (en) Peptides and use thereof
HK40061342A (en) Polypeptides comprising modified il-2 polypeptides and uses thereof
GB202018733D0 (en) Polypeptides and uses thereof
HK40112218A (en) Il-2 muteins and uses thereof
HK40068898A (en) Cd33-binding polypeptides and uses thereof
HK40068899A (en) Clec12a-binding polypeptides and uses thereof
HK40068897A (en) Cd123-binding polypeptides and uses thereof
GB201812328D0 (en) Polypeptides and uses thereof
AU2019903255A0 (en) Polypeptides and uses thereof